Progression free survival (PFS) extended to 9.1 months in ADC resistant patient - quadruple the PFS of patients...
BriaCell doubles Progression-Free-Survival (PFS) and Clinical Benefit Rate vs historical results in the...
PHILADELPHIA and VANCOUVER, British Columbia, May 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp...
Study to evaluate the effects of Bria-OTS™ in combination with anti-PD-1 antibody tislelizumab, in advanced...
83% intracranial objective response rate (iORR) with Bria-IMT™ in heavily pretreated advanced breast cancer...
PHILADELPHIA and VANCOUVER, British Columbia, May 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp...
PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp...
Oral presentation by Mayo Clinic Professor and Principal Investigator, Saranya Chumsri, MDTwo poster...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.